Securities code: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) securities abbreviation: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) Announcement No.: 2022016 Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Performance forecast for the first quarter of 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2022 to March 31, 2022
2. □ the estimated net profit is positive and belongs to one of the following situations:
□ turning losses into profits □ rising in the same direction □ falling in the same direction
The current reporting period of the project is the same period of last year
Shares attributable to listed companies increased by 295.61% – 324.91% over the same period last year
Profit: 3412454 million yuan, net profit of Dongdong: 13501450 million yuan
Shares attributable to listed companies increased by 296.68% – 326.06% over the same period last year
East’s net profit after deducting non recurring profit: 340324800 yuan profit and loss: 1350 million yuan – 1450 million yuan
The basic earnings per share is 128721 yuan / share – 138256 yuan / share and 4.9500 yuan / share
Note 1: the above “ten thousand yuan” refers to ten thousand yuan.
2、 Communication with accounting firms
This performance forecast has not been pre audited by certified public accountants. As the performance forecast has not been audited, Lixin certified public accountants said that it is impossible to judge whether there may be differences with the company in the performance forecast.
3、 Explanation of performance change reasons
1. Since January 2022, the outbreak of Omicron has occurred in many places in China, and the number of new cases in China has reached a new high. In order to prevent and control the epidemic, all localities have increased the frequency of covid-19 nucleic acid detection and increased the demand for covid-19 nucleic acid detection reagent. With the company’s products with high sensitivity, convenient operation and high-quality customer service, the market share of covid-19 nucleic acid detection reagent has continued to rise, Covid-19 nucleic acid detection reagents and services increased significantly.
2. In March 2022, the comprehensive team of the State Council for covid-19 epidemic prevention and control mechanism decided to add antigen detection as a supplement on the basis of nucleic acid detection. On February 19, 2023, the company in Jilin Province repeatedly increased the demand for antigen detection kits of vid-19 and Shanghai, and brought about the operation of new antigen detection kits of vid-15 companies in China.
3. Since January 2022, the overseas Omicron covid-19 epidemic has been repeated, the market demand for covid-19 antigen detection kit has increased, and the company’s export orders for covid-19 antigen detection kit have increased significantly year-on-year.
4、 Risk tips and other relevant instructions
1. Due to the uncertainty and unpredictability of the global covid-19 epidemic development and the epidemic prevention and control policies in China’s foreign markets, the company’s future operating performance is uncertain. Please pay attention to the relevant investment risks.
2. This performance forecast is the preliminary calculation result of the company’s financial department, which has not been audited by the audit institution. The specific financial data shall be subject to the first quarter report of 2022 disclosed by the company. The information disclosure media designated by the company are China Securities Journal, securities times and cninfo (www.cn. Info. Com. CN), Please pay attention to investment risks.
It is hereby announced.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Board of directors
April 14, 2022
